

Annamaria Ferrero

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3788694/publications.pdf>

Version: 2024-02-01

108
papers

4,400
citations

147801

31
h-index

110387

64
g-index

112
all docs

112
docs citations

112
times ranked

4542
citing authors

#	ARTICLE	IF	CITATIONS
1	ESMOâ€“ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. <i>Annals of Oncology</i> , 2019, 30, 672-705.	1.2	665
2	Pegylated Liposomal Doxorubicin and Carboplatin Compared With Paclitaxel and Carboplatin for Patients With Platinum-Sensitive Ovarian Cancer in Late Relapse. <i>Journal of Clinical Oncology</i> , 2010, 28, 3323-3329.	1.6	500
3	Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 295-309.	10.7	426
4	Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 1273-1285.	10.7	305
5	Patterns of recurrence in patients with squamous cell carcinoma of the vulva. <i>Cancer</i> , 2000, 89, 116-122.	4.1	215
6	Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: recurrent disease. <i>Annals of Oncology</i> , 2017, 28, 727-732.	1.2	203
7	SUCCOR study: an international European cohort observational study comparing minimally invasive surgery versus open abdominal radical hysterectomy in patients with stage IB1 cervical cancer. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1269-1277.	2.5	169
8	ESMOâ€“ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 728-760.	2.5	167
9	Randomized Phase III Study of Erlotinib Versus Observation in Patients With No Evidence of Disease Progression After First-Line Platin-Based Chemotherapy for Ovarian Carcinoma: A European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group, and Gynecologic Cancer Intergrøp Study. <i>Journal of Clinical Oncology</i> , 2014, 32, 320-326.	1.6	99
10	Analysis of Failures after Negative Second-Look in Patients with Advanced Ovarian Cancer: An Italian Multicenter Study. <i>Gynecologic Oncology</i> , 1998, 68, 150-155.	1.4	81
11	Impact of Obesity on Surgical Treatment for Endometrial Cancer: AÂ“Multicenter Study Comparing Laparoscopy vs Open Surgery, withÂ“Propensity-Matched Analysis. <i>Journal of Minimally Invasive Gynecology</i> , 2016, 23, 53-61.	0.6	73
12	Laparoscopic identification of pelvic nerves in patients with deep infiltrating endometriosis. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2004, 18, 1109-12.	2.4	63
13	The systemic treatment of recurrent ovarian cancer revisited. <i>Annals of Oncology</i> , 2021, 32, 710-725.	1.2	61
14	The effect of a uterine manipulator on the recurrence and mortality of endometrial cancer: a multi-centric study by the Italian Society of Gynecological Endoscopy. <i>American Journal of Obstetrics and Gynecology</i> , 2017, 216, 592.e1-592.e11.	1.3	59
15	Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial. <i>Annals of Oncology</i> , 2012, 23, 1185-1189.	1.2	57
16	Laparoscopic vs. open treatment of endometrial cancer in the elderly and very elderly: An age-stratified multicenter study on 1606 women. <i>Gynecologic Oncology</i> , 2016, 141, 211-217.	1.4	50
17	Behaviour of ovarian tumors of low malignant potential treated with conservative surgery. <i>European Journal of Surgical Oncology</i> , 2009, 35, 643-648.	1.0	47
18	European Society of Gynecological Oncology Statement on Fibroid and Uterine Morcellation. <i>International Journal of Gynecological Cancer</i> , 2017, 27, 189-192.	2.5	45

#	ARTICLE	IF	CITATIONS
19	Laparoscopic radical hysterectomy: a European Society of Gynaecological Oncology (ESGO) statement. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 15-15.	2.5	45
20	Ovarian Cancer in Elderly Patients: Patterns of Care and Treatment Outcomes According to Age and Modified Frailty Index. <i>International Journal of Gynecological Cancer</i> , 2017, 27, 1863-1871.	2.5	44
21	TOP2A gene copy gain predicts response of epithelial ovarian cancers to pegylated liposomal doxorubicin. <i>Gynecologic Oncology</i> , 2015, 138, 627-633.	1.4	43
22	Secondary cytoreductive surgery for isolated lymph node recurrence of epithelial ovarian cancer: A multicenter study. <i>European Journal of Surgical Oncology</i> , 2014, 40, 891-898.	1.0	40
23	Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in very platinum-sensitive ovarian cancer patients: Results from a subset analysis of the CALYPSO phase III trial. <i>European Journal of Cancer</i> , 2015, 51, 352-358.	2.8	40
24	Health-related quality of life in recurrent platinum-sensitive ovarian cancer—results from the CALYPSO trial. <i>Annals of Oncology</i> , 2012, 23, 2020-2027.	1.2	39
25	Impact of secondary cytoreductive surgery on survival in patients with platinum sensitive recurrent ovarian cancer: Analysis of the CALYPSO trial. <i>Gynecologic Oncology</i> , 2015, 136, 18-24.	1.4	39
26	Malignant struma ovarii: a case report of laparoscopic management. <i>Gynecologic Oncology</i> , 2003, 90, 191-194.	1.4	36
27	The clinical outcome of epithelial ovarian cancer patients with apparently isolated lymph node recurrence: A multicenter retrospective Italian study. <i>Gynecologic Oncology</i> , 2010, 116, 358-363.	1.4	36
28	CA-125 can be part of the tumour evaluation criteria in ovarian cancer trials: experience of the GCIG CALYPSO trial. <i>British Journal of Cancer</i> , 2012, 106, 633-637.	6.4	36
29	The cellular apoptosis susceptibility <i>CAS/CSE1L</i> gene protects ovarian cancer cells from death by suppressing RASSF1C. <i>FASEB Journal</i> , 2012, 26, 2446-2456.	0.5	34
30	EANM guideline on the role of 2-[18F]FDG PET/CT in diagnosis, staging, prognostic value, therapy assessment and restaging of ovarian cancer, endorsed by the American College of Nuclear Medicine (ACNM), the Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the International Atomic Energy Agency (IAEA). <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 3286-3302.	6.4	33
31	Prognostic nomogram to predict progression-free survival in patients with platinum-sensitive recurrent ovarian cancer. <i>British Journal of Cancer</i> , 2011, 105, 1144-1150.	6.4	32
32	Harmonising clinical trials within the Gynecologic Cancer InterGroup: consensus and unmet needs from the Fifth Ovarian Cancer Consensus Conference. <i>Annals of Oncology</i> , 2017, 28, viii30-viii35.	1.2	32
33	Diagnostic accuracy and cost-effectiveness of different strategies to triage women with adnexal masses: a prospective study. <i>Ultrasound in Obstetrics and Gynecology</i> , 2017, 50, 395-403.	1.7	26
34	Clinical and pharmacokinetic phase II study of pegylated liposomal doxorubicin and vinorelbine in heavily pretreated recurrent ovarian carcinoma. <i>Annals of Oncology</i> , 2005, 16, 300-306.	1.2	25
35	Clinical Significance of Microinvasion in Borderline Ovarian Tumors and Its Impact on Surgical Management. <i>International Journal of Gynecological Cancer</i> , 2012, 22, 1158-1162.	2.5	24
36	Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy. <i>Targeted Oncology</i> , 2015, 10, 583-596.	3.6	23

#	ARTICLE	IF	CITATIONS
37	Pretreatment platelet and hemoglobin levels are neither predictive nor prognostic variables for patients with locally advanced cervical cancer treated with neoadjuvant chemotherapy and radical hysterectomy: a retrospective Italian study. <i>International Journal of Gynecological Cancer</i> , 2010, 20, 1399-404.	2.5	22
38	Laparoscopic treatment of endometrial cancer: feasibility and results. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2006, 124, 232-236.	1.1	21
39	Pretreatment serum hemoglobin level as a predictive factor of response to neoadjuvant chemotherapy in patients with locally advanced squamous cervical carcinoma: A preliminary report. <i>Gynecologic Oncology</i> , 2005, 99, S187-S191.	1.4	20
40	TOP2A as marker of response to pegylated liposomal doxorubicin (PLD) in epithelial ovarian cancers. <i>Journal of Ovarian Research</i> , 2019, 12, 17.	3.0	20
41	Bevacizumab, carboplatin, and paclitaxel in the first line treatment of advanced ovarian cancer patients: the phase IV MITO-16A/MaNGO-OV2A study. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 875-882.	2.5	19
42	Suspecting Malignancy in Endometrial Polyps: Value of Hysteroscopy. <i>Tumori</i> , 2013, 99, 204-209.	1.1	17
43	Genital and Peritoneal Tuberculosis: Potential Role of Laparoscopy in Diagnosis and Management. <i>Journal of Minimally Invasive Gynecology</i> , 2004, 11, 269-272.	1.2	16
44	Endometriosis-associated Ovarian Cancer: A Distinct Clinical Entity?. <i>Anticancer Research</i> , 2016, 36, 3445-9.	1.1	16
45	Intratumoral microvessel density in advanced epithelial ovarian cancer and its use as a prognostic variable. <i>Anticancer Research</i> , 2006, 26, 3925-32.	1.1	15
46	Clinical Outcome of Patients With Malignant Tumors Associated With Mature Cystic Teratomas of the Ovary: A Retrospective Multicenter Italian Study. <i>Anticancer Research</i> , 2019, 39, 2513-2517.	1.1	14
47	Can Vulnerable Elders Survey-13 predict the impact of frailty on chemotherapy in elderly patients with gynaecological malignancies?. <i>Medicine (United States)</i> , 2018, 97, e12298.	1.0	13
48	The Search for New 2-18F-FDG PET/CT Imaging Biomarkers in Advanced Ovarian Cancer Patients. <i>Clinical Nuclear Medicine</i> , 2021, 46, 906-907.	1.3	13
49	The role of surgery in recurrent endometrial cancer. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 741-750.	2.4	12
50	Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: A GCG and EORTC-GCC study.. <i>Journal of Clinical Oncology</i> , 2012, 30, LBA5000-LBA5000.	1.6	12
51	Predictors of extensive lymphatic dissemination and recurrences in node-positive endometrial cancer. <i>Gynecologic Oncology</i> , 2019, 154, 480-486.	1.4	11
52	A randomized, phase III study of carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in relapsed platinum-sensitive ovarian cancer (OC): CALYPSO study of the Gynecologic Cancer Intergroup (GCG). <i>Journal of Clinical Oncology</i> , 2009, 27, LBA5509-LBA5509.	1.6	11
53	Characteristics and patterns of care of endometrial cancer before and during COVID-19 pandemic. <i>Journal of Gynecologic Oncology</i> , 2022, 33, e10.	2.2	11
54	Suspecting malignancy in endometrial polyps: value of hysteroscopy. <i>Tumori</i> , 2013, 99, 204-9.	1.1	11

#	ARTICLE	IF	CITATIONS
55	Is carboplatin+paclitaxel combination the standard treatment of elderly ovarian cancer patients?. <i>Annals of Oncology</i> , 2007, 18, 213-214.	1.2	10
56	Angiogenesis and molecular markers in advanced epithelial ovarian cancer: A retrospective study. <i>Gynecologic Oncology</i> , 2011, 123, 301-307.	1.4	10
57	Multicenter, randomised, open-label, non-comparative phase 2 trial on the efficacy and safety of the combination of bevacizumab and trabectedin with or without carboplatin in women with partially platinum-sensitive recurrent ovarian cancer. <i>British Journal of Cancer</i> , 2019, 121, 744-750.	6.4	10
58	Syringoid eccrine carcinoma: Case report of a rare tumor occasionally detected in the vulva. <i>Gynecologic Oncology Case Reports</i> , 2011, 1, 17-19.	0.9	9
59	A Search for Predictive Factors for Hypersensitivity Reactions to Paclitaxel and Platinum Salts in Chemotherapy for Gynecologic Pelvic Neoplasms. <i>Gynecologic and Obstetric Investigation</i> , 2012, 74, 21-27.	1.6	9
60	Complications After the Treatment of Endometrial Cancer: A Prospective Study Using the French-Italian Glossary. <i>International Journal of Gynecological Cancer</i> , 2014, 24, 418-426.	2.5	9
61	Neoadjuvant Platinum-based Chemotherapy Followed by Radical Hysterectomy for Stage Ib2-Ilb Adenocarcinoma of the Uterine Cervix – An Italian Multicenter Retrospective Study. <i>Anticancer Research</i> , 2018, 38, 3627-3634.	1.1	9
62	Clinical pathways of recovery after surgery for advanced ovarian/tubal/peritoneal cancer: an NSGO-MaNGO international survey in collaboration with AGO – a focus on surgical aspects. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 181-187.	2.5	9
63	Laparoscopic neurolysis of the pelvic sciatic nerve in a case of catamenial footdrop. <i>Journal of Minimally Invasive Gynecology</i> , 2005, 12, 525-527.	0.6	8
64	Attitudes of Italian gynaecologists towards prophylactic oophorectomy at hysterectomy for non-malignant conditions. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2006, 124, 82-87.	1.1	8
65	Pegylated liposomal doxorubicin and carboplatin (C-PLD) versus paclitaxel and carboplatin (C-P) in platinum-sensitive ovarian cancer (OC) patients (pts): Treatment at recurrence and overall survival (OS) final analysis from CALYPSO phase III GCIG trial.. <i>Journal of Clinical Oncology</i> , 2011, 29, 5052-5052.	1.6	8
66	Pretreatment serum hemoglobin level and a preliminary investigation of intratumoral microvessel density in advanced ovarian cancer. <i>Gynecologic Oncology</i> , 2004, 95, 323-329.	1.4	7
67	Pre-chemotherapy hemoglobin levels and survival in patients with advanced epithelial ovarian cancer who received a first-line taxane/platinum-based regimen: Results of a multicenter retrospective Italian study. <i>Gynecologic Oncology</i> , 2005, 98, 118-123.	1.4	7
68	Medical treatment of early stage and rare histological variants of epithelial ovarian cancer. <i>Ecanermedicalscience</i> , 2015, 9, 584.	1.1	7
69	Intensive versus minimalist follow-up in patients treated for endometrial cancer: A multicentric randomized controlled trial (The TOTEM study – NCT00916708).. <i>Journal of Clinical Oncology</i> , 2021, 39, 5506-5506.	1.6	7
70	Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: A GCIG and EORTC-GCG study.. <i>Journal of Clinical Oncology</i> , 2012, 30, LBA5000-LBA5000.	1.6	7
71	Rates, Sites and Times of Recurrence and Clinical Outcome of Endometrial Cancer Patients with Histologically-positive Nodes: An Italian Two-center Retrospective Study. <i>Anticancer Research</i> , 2018, 38, 1695-1703.	1.1	6
72	Gemcitabine and Vinorelbine Combination in Platinum-Sensitive Recurrent Ovarian Cancer. <i>International Journal of Gynecological Cancer</i> , 2009, 19, 1529-1534.	2.5	5

#	ARTICLE	IF	CITATIONS
73	Is Ovarian Cancer Being Managed According to Clinical Guidelines? Evidence From a Population-Based Clinical Audit. <i>International Journal of Gynecological Cancer</i> , 2016, 26, 1615-1623.	2.5	5
74	Hypersensitivity to platinum salts according to BRCA status in ovarian cancer: A retrospective analysis of clinical outcomes and systematic review of literature. <i>Gynecologic Oncology</i> , 2021, 162, 80-87.	1.4	5
75	Association between ovarian endometriosis and malignancy in the peri-menopausal period: report of two cases and review of the literature. <i>Gynecological Surgery</i> , 2010, 7, 13-17.	0.9	4
76	The Retrograde and Retroperitoneal Totally Laparoscopic Hysterectomy for Endometrial Cancer. <i>International Journal of Surgical Oncology</i> , 2012, 2012, 1-5.	0.6	4
77	Metastatic Bilateral Strumal Carcinoid: A Case Report and Review of the Literature. <i>Anticancer Research</i> , 2019, 39, 5053-5056.	1.1	4
78	Development of a preoperative computed tomography score for the management of advanced epithelial ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 599-604.	2.5	4
79	Oral metronomic cyclophosphamide in advanced ovarian cancer. <i>Anti-Cancer Drugs</i> , 2019, 30, 964-968.	1.4	4
80	Postoperative chemotherapy or no further treatment for patients with node-negative stage I-II intermediate or high risk endometrial cancer: The ENGOT-EN2/DGCG trial.. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS5613-TPS5613.	1.6	4
81	Analysis of the Evolution in the Management of Endometrial Cancer in Italy: A CTF Study. <i>Tumori</i> , 2002, 88, 481-488.	1.1	3
82	Laparoscopic dissection of the ureter for radical laparoscopic hysterectomy. <i>Gynecological Surgery</i> , 2005, 2, 179-182.	0.9	3
83	Daily administration of low molecular weight heparin increases Hepatocyte Growth Factor serum levels in gynaecological patients: pharmacokinetic parameters and clinical implications. <i>BMC Research Notes</i> , 2012, 5, 517.	1.4	3
84	Thromboembolic events and antithrombotic prophylaxis in advanced ovarian cancer patients treated with bevacizumab: secondary analysis of the phase IV MITO-16A/MaNGO-OV2A trial. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 1348-1355.	2.5	3
85	Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in very platinum-sensitive ovarian cancer patients: Results from a subset analysis of the CALYPSO phase III GCIG trial.. <i>Journal of Clinical Oncology</i> , 2011, 29, 5059-5059.	1.6	3
86	The role of the French-Italian glossary of complications in the outcome evaluation of cervical cancer treatment: an Italian multicentric study. <i>Critical Reviews in Oncology/Hematology</i> , 2003, 48, 317-321.	4.4	2
87	Laparoscopic restaging of ovarian granulosa cells tumor: three cases report. <i>Gynecological Surgery</i> , 2009, 6, 77-81.	0.9	2
88	Is it time to include [18F]FDG-PET/CT in the diagnostic work-up for lymph node staging in cN0 vulvar cancer patients?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 3043-3045.	6.4	2
89	Predicting Response to Anthracyclines in Ovarian Cancer. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 4260.	2.6	2
90	Laparoscopic Bipolar Coagulation of Hypogastric Artery in Postpartum Haemorrhage: A Case Report. <i>Case Reports in Obstetrics and Gynecology</i> , 2011, 2011, 1-3.	0.3	1

#	ARTICLE	IF	CITATIONS
91	EORTC Gynecological Cancer Group on the frontline of practice-changing clinical trials. European Journal of Cancer, Supplement, 2012, 10, 66-75.	2.2	1
92	Impact of Bevacizumab-containing Primary Treatment on Outcome of Recurrent Ovarian Cancer: An Italian Study. Anticancer Research, 2020, 40, 1543-1550.	1.1	1
93	Could a 2D/3D US based model be helpful in the assessment of myometrial invasion at time of intraoperative frozen section? A pilot study. Minerva Obstetrics and Gynecology, 2021, 73, 362-368.	1.0	1
94	A phase III trial of postoperative chemotherapy or no further treatment for patients with node-negative stage I-II intermediate- or high-risk endometrial cancer. ENGOT-EN2-DGCG/EORTC 55102.. Journal of Clinical Oncology, 2014, 32, TPS5628-TPS5628.	1.6	1
95	â€œSee and treat hysteroscopyâ€ in the management of endometrial polyp. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2016, 206, e78.	1.1	0
96	Food habits and risk of endometrial cancer: development of an assessment questionnaire. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2016, 206, e7.	1.1	0
97	â€œSee and treat hysteroscopyâ€ in the management of endometrial polyp. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2016, 206, e170.	1.1	0
98	Clinico-pathological features of endometrial cancer in Lynch Syndrome patients in comparison with the general population. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2016, 206, e138.	1.1	0
99	Chemotherapy and uterine sarcomas: a narrative review. Gynecology and Pelvic Medicine, 0, .	0.1	0
100	Health-related quality of life (HRQL) and progression-free survival (PFS) in patients with recurrent ovarian cancer: Results from the CALYPSO trial.. Journal of Clinical Oncology, 2010, 28, 5044-5044.	1.6	0
101	Low Malignant Potential Tumors. ISGE Series, 2015, , 191-198.	0.2	0
102	P73â€..Is intraoperative frozen section needed to assess myometrial infiltration in endometrial cancer (EC)? A multicentre study in oncological network of piemonte and valle dâ€™aosta. , 2019, , .		0
103	EP518â€..â€ Sandwichâ€™ adjuvant chemotherapy and radiotherapy in high risk endometrial cancer: two institution experience. , 2019, , .		0
104	EP1075â€..Immunohistochemistry improves specificity in the diagnosis of preneoplastic fallopian tube lesions of BRCA mutation carriers. , 2019, , .		0
105	Hypersensitivity to platinum salts according to BRCA status in ovarian cancer: Retrospective analysis of clinical outcomes.. Journal of Clinical Oncology, 2020, 38, 6053-6053.	1.6	0
106	506â€..Oral metronomic cyclophosphamide in recurrent ovarian cancer: a single centre experience. , 2020, , .		0
107	492â€..Endometrial cancer: the role of prognostic factors and their impact on recurrence pattern. , 2020, , .		0
108	How challenging could be preoperative and intraoperative diagnosis of endometrial cancer?. Minerva Obstetrics and Gynecology, 2022, , .	1.0	0